Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

High -dose methotrexate with folinic acid (FA) rescue is the preferred treatment for primary central nervous system lymphoma. However, FA dosing regimens vary widely, and the effect of different doses on treatment outcomes remains unknown. In this study of 36 PCNSL patients, higher per -treatment cumulative FA doses were linked to worse progression -free survival. Introduction: High -dose methotrexate (HDMTX)-based regimens are the treatment of choice in primar y central ner vous system lymphoma (PCNSL). Folinic acid (FA) rescue is used to mitigate the toxic effects of MTX on normal cells. However, the optimal dosing of FA in PCNSL remains uncertain. Methods: We analyzed the relationship between FA dosing and treatment efficacy and toxicity in a cohort of 36 PCNSL patients treated at our institute between the years 2014 and 2022. A combination of univariate and multivariate analyses using known prognostic factors were used to determine the association between FA dosing and treatment outcomes. Results: We found that higher per -treatment cumulative FA doses were associated with inferior progression -free survival (PFS), with a hazard ratio (HR) of 2.2 for each 100 mg/m2 increase in FA dose. We identified a threshold of 350 mg/m2 /treatment, above which there was a significant reduction in PFS. Notably, lower FA doses did not result in increased toxicity. Conclusion: Our findings suggest that optimizing FA dosing to avoid very high rescue doses may improve treatment outcomes in PCNSL patients receiving HDMTX. Further prospective studies are warranted to validate these findings.